{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T20:55:04Z","timestamp":1760820904078,"version":"3.38.0"},"reference-count":52,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Luminex multiplex immunoassays enable simultaneous monitoring of Abs against multiple Ags in autoimmune, inflammatory, and infectious diseases. The assays are used extensively to monitor anti-HLA Abs in transplant patients for donor organ selection, desensitization, and assessing the risk for graft rejection. To monitor IgG Abs, fluoresceinated IgG constant H chain\u2013binding polyclonal F(ab\u2032)2 (IgHPolyFab) is used as the fluoresceinated secondary Ab (2nd-Ab), whereas IgG subclasses are monitored with Fc-specific monoclonal whole IgG (FcMonoIgG). The fluorescent signal from the 2nd-Ab is measured as mean florescence intensity (MFI). When IgHPolyFab is used, the signal is amplified as a result of the binding of multiple polyclonal Fabs to the C region of primary IgH. The reliability of such amplification for Ab measurements was not validated, nor were MFIs compared with 1:1 binding of FcMonoIgG to primary Abs. Comparing the MFIs of anti-HLA Abs obtained with IgHPolyFab and FcMonoIgG against normal human sera, IVIg, and allograft recipients\u2019 sera, it was observed that the number of HLA-Abs was notably higher with IgHPolyFab than with FcMonoIgG. The MFIs of anti-HLA Abs also remained higher with IgHPolyFab in the normal sera and in IVIg, but the reverse was true when the autologous and allogeneic IgG concentrations were augmented in allograft recipients. Indeed, MFIs of the de novo allo-HLA Abs were markedly higher with FcMonoIgG than with IgHPolyFab. Serum titration established the superiority of FcMonoIgG for monitoring MFIs of de novo allo-HLA Abs in allograft recipients. Avoiding false amplifications of the number and MFIs of anti-HLA IgG with FcMonoIgG may minimize immunosuppressive therapies, maximize the number of donors for patients waiting for allografts, and enable better prediction of graft rejection.<\/jats:p>","DOI":"10.4049\/jimmunol.1700050","type":"journal-article","created":{"date-parts":[[2017,5,6]],"date-time":"2017-05-06T00:20:21Z","timestamp":1494030021000},"page":"4524-4538","source":"Crossref","is-referenced-by-count":9,"title":["Nature and Clonality of the Fluoresceinated Secondary Antibody in Luminex Multiplex Bead Assays Are Critical Factors for Reliable Monitoring of Serum HLA Antibody Levels in Patients for Donor Organ Selection, Desensitization Therapy, and Assessment of the Risk for Graft Loss"],"prefix":"10.1093","volume":"198","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5731-4129","authenticated-orcid":false,"given":"Mepur H","family":"Ravindranath","sequence":"first","affiliation":[{"name":"Terasaki Foundation Laboratory , Los Angeles, CA 90064"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0385-2623","authenticated-orcid":false,"given":"Vadim","family":"Jucaud","sequence":"additional","affiliation":[{"name":"Terasaki Foundation Laboratory , Los Angeles, CA 90064"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nubia","family":"Banuelos","sequence":"additional","affiliation":[{"name":"Terasaki Foundation Laboratory , Los Angeles, CA 90064"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew J","family":"Everly","sequence":"additional","affiliation":[{"name":"Terasaki Foundation Laboratory , Los Angeles, CA 90064"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junchao","family":"Cai","sequence":"additional","affiliation":[{"name":"Terasaki Foundation Laboratory , Los Angeles, CA 90064"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anh","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Terasaki Foundation Laboratory , Los Angeles, CA 90064"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul I","family":"Terasaki","sequence":"additional","affiliation":[{"name":"Terasaki Foundation Laboratory , Los Angeles, CA 90064"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2017,6,1]]},"reference":[{"key":"2025030615151787000_r1","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/cei.12724","article-title":"Serum antibodies to human leucocyte antigen (HLA)-E, HLA-F and HLA-G in patients with systemic lupus erythematosus (SLE) during disease flares: clinical relevance of HLA-F autoantibodies","volume":"183","author":"Jucaud","year":"2016","journal-title":"Clin. Exp. Immunol."},{"key":"2025030615151787000_r2","doi-asserted-by":"crossref","first-page":"850","DOI":"10.7150\/ijms.8633","article-title":"Presence of antibodies against self human leukocyte antigen class II molecules in autoimmune hepatitis","volume":"11","author":"Yamagiwa","year":"2014","journal-title":"Int. J. Med. Sci."},{"key":"2025030615151787000_r3","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1007\/s12016-010-8241-z","article-title":"Geographical differences in autoantibodies and anti-infectious agents antibodies among healthy adults","volume":"42","author":"Shapira","year":"2012","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"2025030615151787000_r4","first-page":"53","article-title":"Autoantibodies profile in the sera of patients with Sjogren\u2019s syndrome: the ANA evaluation--a homogeneous, multiplexed system","volume":"11","author":"Gilburd","year":"2004","journal-title":"Clin. Dev. Immunol."},{"key":"2025030615151787000_r5","doi-asserted-by":"crossref","first-page":"282","DOI":"10.3109\/1547691X.2011.645582","article-title":"Augmentation of anti-HLA-E antibodies with concomitant HLA-Ia reactivity in IFN\u03b3-treated autologous melanoma cell vaccine recipients","volume":"9","author":"Ravindranath","year":"2012","journal-title":"J. Immunotoxicol."},{"key":"2025030615151787000_r6","doi-asserted-by":"crossref","first-page":"570","DOI":"10.3389\/fimmu.2016.00570","article-title":"Detection of HLA antibodies in organ transplant recipients- triumphs and challenges of the solid phase bead assay","volume":"7","author":"Tait","year":"2016","journal-title":"Front. Immunol."},{"key":"2025030615151787000_r7","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1111\/ajt.12287","article-title":"Comprehensive assessment and standardization of solid phase multiplex-bead arrays for the detection of antibodies to HLA","volume":"13","author":"Reed","year":"2013","journal-title":"Am. J. Transplant."},{"key":"2025030615151787000_r8","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1373\/clinchem.2004.047084","article-title":"Multiplexed analysis of biomarkers related to obesity and the metabolic syndrome in human plasma, using the Luminex-100 system","volume":"51","author":"Liu","year":"2005","journal-title":"Clin. Chem."},{"key":"2025030615151787000_r9","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/S0198-8859(99)00121-4","article-title":"Flow cytometric detection of HLA antibodies using a spectrum of microbeads","volume":"60","author":"Pei","year":"1999","journal-title":"Hum. Immunol."},{"key":"2025030615151787000_r10","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/00007890-200301150-00008","article-title":"Single human leukocyte antigen flow cytometry beads for accurate identification of human leukocyte antigen antibody specificities","volume":"75","author":"Pei","year":"2003","journal-title":"Transplantation"},{"key":"2025030615151787000_r11","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1097\/TP.0b013e318199c581","article-title":"Detection of immunoglobulin G human leukocyte antigen-specific alloantibodies in renal transplant patients using single-antigen-beads is compromised by the presence of immunoglobulin M human leukocyte antigen-specific alloantibodies","volume":"87","author":"Kosmoliaptsis","year":"2009","journal-title":"Transplantation"},{"key":"2025030615151787000_r12","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/j.humimm.2016.02.008","article-title":"Deciphering IgM interference in IgG anti-HLA antibody detection with flow beads assays","volume":"77","author":"Visentin","year":"2016","journal-title":"Hum. Immunol."},{"key":"2025030615151787000_r13","doi-asserted-by":"crossref","first-page":"4347","DOI":"10.1002\/jps.21328","article-title":"Shaken, not stirred: mechanical stress testing of an IgG1 antibody","volume":"97","author":"Kiese","year":"2008","journal-title":"J. Pharm. Sci."},{"key":"2025030615151787000_r14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.trim.2014.10.003","article-title":"Concordance and discordance in anti-HLA antibody testing","volume":"32","author":"Israeli","year":"2015","journal-title":"Transpl. Immunol."},{"key":"2025030615151787000_r15","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.ejpb.2004.12.004","article-title":"Induction and analysis of aggregates in a liquid IgG1-antibody formulation","volume":"59","author":"Mahler","year":"2005","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"2025030615151787000_r16","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ejps.2009.06.001","article-title":"Structural properties of monoclonal antibody aggregates induced by freeze-thawing and thermal stress","volume":"38","author":"Hawe","year":"2009","journal-title":"Eur. J. Pharm. Sci."},{"key":"2025030615151787000_r17","doi-asserted-by":"crossref","first-page":"25118","DOI":"10.1074\/jbc.M110.160457","article-title":"Classification and characterization of therapeutic antibody aggregates","volume":"286","author":"Joubert","year":"2011","journal-title":"J. Biol. Chem."},{"key":"2025030615151787000_r18","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1097\/TP.0000000000001420","article-title":"Conformational variants of the individual HLA-I antigens on Luminex single antigen beads used in monitoring HLA antibodies: problems and solutions","volume":"101","author":"Jucaud","year":"2017","journal-title":"Transplantation"},{"key":"2025030615151787000_r19","doi-asserted-by":"crossref","first-page":"e153","DOI":"10.1097\/TP.0000000000001629","article-title":"Conformational variants of HLA-I antigens on Luminex single antigen beads for monitoring antibodies","volume":"101","author":"Ravindranath","year":"2017","journal-title":"Transplantation"},{"key":"2025030615151787000_r20","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jim.2008.10.002","article-title":"Validation and comparison of two multiplex technologies, Luminex and Mesoscale Discovery, for human cytokine profiling","volume":"340","author":"Chowdhury","year":"2009","journal-title":"J. Immunol. Methods"},{"key":"2025030615151787000_r21","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/cyto.b.20021","article-title":"Multiplex bead array assays for detection of soluble cytokines: comparisons of sensitivity and quantitative values among kits from multiple manufacturers","volume":"61","author":"Khan","year":"2004","journal-title":"Cytometry B Clin. Cytom."},{"key":"2025030615151787000_r22","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1373\/clinchem.2006.067595","article-title":"Development and validation of a multiplex add-on assay for sepsis biomarkers using xMAP technology","volume":"52","author":"Kofoed","year":"2006","journal-title":"Clin. Chem."},{"key":"2025030615151787000_r23","doi-asserted-by":"crossref","first-page":"227","DOI":"10.4137\/BMI.S660","article-title":"Comparison of the calibration standards of three commercially available multiplex kits for human cytokine measurement to WHO standards reveals striking differences","volume":"3","author":"Nechansky","year":"2008","journal-title":"Biomark. Insights"},{"key":"2025030615151787000_r24","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1177\/1087057110362099","article-title":"Quantitative validation and comparison of multiplex cytokine kits","volume":"15","author":"Richens","year":"2010","journal-title":"J. Biomol. Screen."},{"key":"2025030615151787000_r25","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1084\/jem.132.2.211","article-title":"An analysis of the sequences of the variable regions of Bence Jones proteins and myeloma light chains and their implications for antibody complementarity","volume":"132","author":"Wu","year":"1970","journal-title":"J. Exp. Med."},{"key":"2025030615151787000_r26"},{"key":"2025030615151787000_r27","first-page":"413","article-title":"Immunoglobulin G subclass analysis of HLA donor specific antibodies in heart and renal transplant recipients","volume":"2013","author":"Cicciarelli","year":"2013","journal-title":"Clin. Transpl."},{"key":"2025030615151787000_r28","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1093\/intimm\/dxr094","article-title":"Antibodies to HLA-E may account for the non-donor-specific anti-HLA class-Ia antibodies in renal and liver transplant recipients","volume":"24","author":"Ravindranath","year":"2012","journal-title":"Int. Immunol."},{"key":"2025030615151787000_r29","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1182\/blood-2012-08-447771","article-title":"Therapeutic preparations of IVIg contain naturally occurring anti-HLA-E antibodies that react with HLA-Ia (HLA-A\/-B\/-Cw) alleles","volume":"121","author":"Ravindranath","year":"2013","journal-title":"Blood"},{"key":"2025030615151787000_r30","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/cei.12450","article-title":"Immunoglobulin (Ig)G purified from human sera mirrors intravenous Ig human leucocyte antigen (HLA) reactivity and recognizes one\u2019s own HLA types, but may be masked by Fab complementarity-determining region peptide in the native sera","volume":"179","author":"Ravindranath","year":"2015","journal-title":"Clin. Exp. Immunol."},{"key":"2025030615151787000_r31","first-page":"189","article-title":"Donor-specific HLA antibody response in clonal deletion","volume":"2008","author":"Kaneku","year":"2008","journal-title":"Clin. Transpl."},{"key":"2025030615151787000_r32","first-page":"229","article-title":"Elimination of post-transplant donor-specific HLA antibodies with bortezomib","volume-title":"Clin. Transpl.","author":"Idica","year":"2008"},{"key":"2025030615151787000_r33","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1097\/TP.0b013e3181a4b91b","article-title":"Abrogation of anti-HLA antibodies via proteasome inhibition","volume":"87","author":"Trivedi","year":"2009","journal-title":"Transplantation"},{"key":"2025030615151787000_r34","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/TP.0b013e3181dde912","article-title":"Clonal deletion with bortezomib followed by low or no maintenance immunosuppression in renal allograft recipients","volume":"90","author":"Trivedi","year":"2010","journal-title":"Transplantation"},{"key":"2025030615151787000_r35","first-page":"293","article-title":"Anti-HLA-E monoclonal antibodies reacting with HLA-la and lb alleles like IVIg as potential IVIg-immunomimetics: an evolving therapeutic concept","volume":"2013","author":"Ravindranath","year":"2013","journal-title":"Clin. Transpl."},{"key":"2025030615151787000_r36","doi-asserted-by":"crossref","first-page":"261","DOI":"10.5500\/wjt.v5.i4.261","article-title":"Immunomodulation with rabbit anti-thymocyte globulin in solid organ transplantation","volume":"5","author":"Ippoliti","year":"2015","journal-title":"World J. Transplant."},{"key":"2025030615151787000_r37","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.2165\/11319260-000000000-00000","article-title":"Immunosuppressive drugs in kidney transplantation: impact on patient survival, and incidence of cardiovascular disease, malignancy and infection","volume":"69","author":"Marc\u00e9n","year":"2009","journal-title":"Drugs"},{"key":"2025030615151787000_r38","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.1399-3062.2009.00372.x","article-title":"Cytomegalovirus infection and disease in the new era of immunosuppression following solid organ transplantation","volume":"11","author":"Fisher","year":"2009","journal-title":"Transpl. Infect. Dis."},{"key":"2025030615151787000_r39","first-page":"6","article-title":"Infectious complications in immunosuppressed patients after kidney transplantation","volume":"16","author":"Scherbaum","year":"1988","journal-title":"Immun. Infekt."},{"key":"2025030615151787000_r40","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/S0272-2712(18)30549-3","article-title":"Laboratory evaluations of infections in immunosuppressed transplant patients","volume":"11","author":"Ho","year":"1991","journal-title":"Clin. Lab. Med."},{"key":"2025030615151787000_r41","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0749-0704(18)30348-8","article-title":"Problems related to immunosuppression. Infection and malignancy occurring after solid organ transplantation","volume":"6","author":"Dunn","year":"1990","journal-title":"Crit. Care Clin."},{"key":"2025030615151787000_r42","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1007\/BF02389877","article-title":"Fungal and bacterial infections in the immunocompromised host","volume":"12","author":"Rubin","year":"1993","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"2025030615151787000_r43","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1089\/109629601750469429","article-title":"Hazardous crossing: immunosuppression and nosocomial infections in solid organ transplant recipients","volume":"2","author":"Dunn","year":"2001","journal-title":"Surg. Infect. (Larchmt)"},{"key":"2025030615151787000_r44","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/0966-3274(95)80030-1","article-title":"Influence of anti-IgG antibodies on graft outcome in live related donor renal transplantation","volume":"3","author":"Tahir","year":"1995","journal-title":"Transpl. Immunol."},{"key":"2025030615151787000_r45","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/0966-3274(94)90066-3","article-title":"Effect of panel reactive antibody on live related donor kidney transplantation: Indian experience","volume":"2","author":"Tahir","year":"1994","journal-title":"Transpl. Immunol."},{"key":"2025030615151787000_r46","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/0165-2478(90)90133-B","article-title":"Role of anti-IgG autoantibodies in kidney transplantation","volume":"26","author":"S\u00fcsal","year":"1990","journal-title":"Immunol. Lett."},{"key":"2025030615151787000_r47","doi-asserted-by":"crossref","first-page":"650","DOI":"10.3389\/fimmu.2016.00650","article-title":"Autologous and allogenous antibodies in lung and islet cell transplantation","volume":"7","author":"Nayak","year":"2016","journal-title":"Front. Immunol."},{"key":"2025030615151787000_r48","doi-asserted-by":"crossref","first-page":"371","DOI":"10.2147\/VHRM.S110600","article-title":"Comparison of the acute-phase response after laparoscopic versus open aortobifemoral bypass surgery: a substudy of a randomized controlled trial","volume":"12","author":"Krog","year":"2016","journal-title":"Vasc. Health Risk Manag."},{"key":"2025030615151787000_r49","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1744-313X.2009.00854.x","article-title":"The influence of class II transactivator and interleukin-6 polymorphisms on the production of antibodies to donor human leucocyte antigen mismatches in renal allograft recipients","volume":"36","author":"Martin","year":"2009","journal-title":"Int. J. Immunogenet."},{"key":"2025030615151787000_r50","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.cytogfr.2012.04.001","article-title":"Plasticity and cross-talk of interleukin 6-type cytokines","volume":"23","author":"Garbers","year":"2012","journal-title":"Cytokine Growth Factor Rev."},{"key":"2025030615151787000_r51","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1097\/BOR.0000000000000255","article-title":"The biology behind interleukin-6 targeted interventions","volume":"28","author":"Liu","year":"2016","journal-title":"Curr. Opin. Rheumatol."},{"key":"2025030615151787000_r52","first-page":"314","article-title":"Interleukin 6 (IL-6) in serum and urine of renal transplant recipients","volume":"71","author":"Van Oers","year":"1988","journal-title":"Clin. Exp. Immunol."}],"container-title":["The Journal of Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jimmunol\/article-pdf\/198\/11\/4524\/61449831\/1700050.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jimmunol\/article-pdf\/198\/11\/4524\/61449831\/1700050.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T17:35:30Z","timestamp":1741282530000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jimmunol\/article\/198\/11\/4524\/7954973"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,1]]},"references-count":52,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2017,6,1]]}},"URL":"https:\/\/doi.org\/10.4049\/jimmunol.1700050","relation":{},"ISSN":["0022-1767","1550-6606"],"issn-type":[{"type":"print","value":"0022-1767"},{"type":"electronic","value":"1550-6606"}],"subject":[],"published-other":{"date-parts":[[2017,6]]},"published":{"date-parts":[[2017,6,1]]}}}